

**A PHASE II STUDY OF GEMCITABINE PLUS CISPLATIN CHEMOTHERAPY IN PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER WITH BLADDER PRESERVATION FOR THOSE PATIENTS WHOSE TUMORS HARBOR DELETERIOUS DNA DAMAGE RESPONSE (DDR) GENE ALTERATIONS**

**Eligibility Criteria (see Section 3.0)**


Histologically confirmed urothelial carcinoma of the bladder  
 10-20 unstained slides or 1 FFPE block from pre-treatment TUR available  
 Clinical stage T2-T4aNO/xM0  
 Candidate for radical cystectomy  
 No prior systemic chemotherapy or radiation therapy for the bladder  
 No major surgery or RT  $\leq$  4 weeks  
 Non-pregnant and non-nursing  
 Age  $\geq$  18 years  
 ECOG PS = 0-1  
 No comorbid conditions per Section 3.2.9

**Required Initial Laboratory Values**

Absolute neutrophil count (ANC):  $\geq 1000/\text{mm}^3$   
 Platelet count:  $\geq 100,000/\text{mm}^3$   
 Calc. creatinine clearance:  $\geq 55 \text{ mL/min}$   
 Total bilirubin:  $\leq 1.5 \times \text{ULN}$   
 (For patients with documented Gilbert's syndrome Bilirubin  $\leq 3 \times \text{ULN}$ )  
 AST/ALT:  $\leq 2.5 \times \text{ULN}$   
 Alkaline phosphatase:  $\leq 2.5 \times \text{ULN}$

1 Cycle = 14 days for ddGC

1 Cycle = 21 days for Standard GC



Chemotherapy is to continue for 6 cycles or unacceptable adverse events (at least 4 cycles must be given for patients to proceed to Step 2 registration). Patients on the standard treatment (gemcitabine on days 1 and 8 and cisplatin on day 1) must receive 4 cycles to proceed to Step 2 registration. Patients will be followed for five years after completion of chemotherapy or radical cystectomy, or until death, whichever comes first.

**Please refer to the full protocol text for a complete description of the eligibility criteria and treatment plan.**